Stock listing
Dusseldorf:OEZ Avecho Biotechnology Limited Aktie
German listing (Dusseldorf) of Avecho Biotechnology Limited · home listing ASX:AVE
Follow Avecho Biotechnology Limited into a list and get an email when it puts out news.
Home listing price · ASX:AVE
$0.012 AUD 0.000 (0.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, ASX:AVE
- Day range
- $0.011 – $0.012 AUDNov 20, 2026
- Volume
- 1.81M sharesNov 20, 2026
- Market cap
- $46.36M AUDAt the close on Nov 20, 2026 · price × 3.86B shares outstanding
- 52-week range
- $0.0060 – $0.027 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $65,320 AUDMedian day 2.22M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:AVE · Home | $0.012 AUD | 0.000 (0.0%) | 1,808,579 | $0.012 | $0.012 | $0.011 | $0.012 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:AVE · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.012 | 0.000 | 0.0% | $0.012 | $0.012 | $0.011 | 1,808,579 | |
| $0.012 | -0.001 | -7.7% | $0.013 | $0.013 | $0.012 | 696,050 | |
| $0.013 | +0.001 | +8.3% | $0.012 | $0.013 | $0.012 | 2,181,663 | |
| $0.012 | +0.002 | +20.0% | $0.010 | $0.013 | $0.010 | 9,741,007 | |
| $0.010 | -0.001 | -9.1% | $0.011 | $0.011 | $0.010 | 1,005,654 | |
| $0.011 | -0.001 | -8.3% | $0.012 | $0.012 | $0.011 | 5,808,688 | |
| $0.012 | +0.001 | +9.1% | $0.011 | $0.012 | $0.011 | 1,475,045 | |
| $0.011 | -0.001 | -8.3% | $0.013 | $0.013 | $0.011 | 1,357,050 | |
| $0.012 | 0.000 | 0.0% | $0.013 | $0.013 | $0.012 | 1,835,710 | |
| $0.012 | -0.001 | -7.7% | $0.013 | $0.013 | $0.012 | 589,655 | |
| $0.013 | 0.000 | 0.0% | $0.013 | $0.013 | $0.012 | 930,324 | |
| $0.013 | 0.000 | 0.0% | $0.013 | $0.013 | $0.012 | 1,378,169 | |
| $0.013 | 0.000 | 0.0% | $0.013 | $0.013 | $0.012 | 402,805 | |
| $0.013 | -0.001 | -7.1% | $0.013 | $0.014 | $0.013 | 1,650,976 | |
| $0.014 | +0.001 | +7.7% | $0.014 | $0.014 | $0.013 | 4,035,587 | |
| $0.013 | -0.002 | -13.3% | $0.014 | $0.014 | $0.013 | 1,255,918 | |
| $0.015 | +0.001 | +7.1% | $0.015 | $0.015 | $0.013 | 16,577,033 | |
| $0.014 | 0.000 | 0.0% | $0.014 | $0.014 | $0.014 | 1,746,522 | |
| $0.014 | 0.000 | 0.0% | $0.014 | $0.014 | $0.014 | 2,273,853 | |
| $0.014 | -0.001 | -6.7% | $0.017 | $0.017 | $0.013 | 14,770,432 | |
| $0.015 | -0.002 | -11.8% | $0.016 | $0.017 | $0.015 | 1,566,650 | |
| $0.017 | +0.003 | +21.4% | $0.014 | $0.020 | $0.014 | 11,183,884 | |
| $0.014 | 0.000 | 0.0% | $0.014 | $0.015 | $0.014 | 1,900,185 | |
| $0.014 | 0.000 | 0.0% | $0.015 | $0.015 | $0.014 | 1,823,066 | |
| $0.014 | -0.001 | -6.7% | $0.015 | $0.015 | $0.014 | 4,765,850 | |
| $0.015 | +0.002 | +15.4% | $0.014 | $0.015 | $0.013 | 6,372,228 | |
| $0.013 | -0.004 | -23.5% | $0.016 | $0.016 | $0.013 | 22,045,285 | |
| $0.017 | +0.001 | +6.3% | $0.016 | $0.017 | $0.016 | 4,509,419 | |
| $0.016 | 0.000 | 0.0% | $0.016 | $0.016 | $0.016 | 1,382,307 | |
| $0.016 | -0.002 | -11.1% | $0.018 | $0.018 | $0.016 | 7,770,263 | |
| $0.018 | -0.002 | -10.0% | $0.019 | $0.019 | $0.018 | 2,778,789 | |
| $0.020 | +0.001 | +5.3% | $0.020 | $0.020 | $0.019 | 334,869 | |
| $0.019 | 0.000 | 0.0% | $0.019 | $0.020 | $0.019 | 1,779,809 | |
| $0.019 | -0.001 | -5.0% | $0.020 | $0.020 | $0.019 | 518,254 | |
| $0.020 | +0.002 | +11.1% | $0.019 | $0.020 | $0.019 | 554,901 | |
| $0.018 | -0.001 | -5.3% | $0.020 | $0.020 | $0.017 | 8,031,064 | |
| $0.019 | 0.000 | 0.0% | $0.020 | $0.021 | $0.019 | 1,243,636 | |
| $0.019 | 0.000 | 0.0% | $0.020 | $0.020 | $0.019 | 2,233,415 | |
| $0.019 | -0.001 | -5.0% | $0.021 | $0.021 | $0.019 | 5,161,544 | |
| $0.020 | -0.001 | -4.8% | $0.021 | $0.021 | $0.019 | 3,496,337 | |
| $0.021 | +0.001 | +5.0% | $0.022 | $0.022 | $0.020 | 578,258 | |
| $0.020 | -0.002 | -9.1% | $0.021 | $0.022 | $0.020 | 1,688,221 | |
| $0.022 | +0.003 | +15.8% | $0.019 | $0.022 | $0.019 | 2,486,114 | |
| $0.019 | -0.001 | -5.0% | $0.021 | $0.021 | $0.019 | 1,606,849 | |
| $0.020 | -0.001 | -4.8% | $0.021 | $0.021 | $0.020 | 3,943,198 | |
| $0.021 | +0.001 | +5.0% | $0.021 | $0.021 | $0.020 | 1,145,121 | |
| $0.020 | 0.000 | 0.0% | $0.021 | $0.021 | $0.020 | 2,146,170 | |
| $0.020 | -0.001 | -4.8% | $0.021 | $0.021 | $0.020 | 1,486,757 | |
| $0.021 | -0.001 | -4.5% | $0.022 | $0.022 | $0.020 | 194,290 | |
| $0.022 | +0.001 | +4.8% | $0.022 | $0.022 | $0.021 | 2,213,643 | |
| $0.021 | -0.002 | -8.7% | $0.022 | $0.023 | $0.021 | 5,593,166 | |
| $0.023 | +0.003 | +15.0% | $0.020 | $0.023 | $0.020 | 7,459,306 | |
| $0.020 | +0.001 | +5.3% | $0.019 | $0.021 | $0.019 | 3,585,996 | |
| $0.019 | -0.002 | -9.5% | $0.021 | $0.021 | $0.019 | 5,180,676 | |
| $0.021 | 0.000 | 0.0% | $0.020 | $0.021 | $0.020 | 3,540,674 | |
| $0.021 | -0.001 | -4.5% | $0.021 | $0.021 | $0.020 | 3,387,664 | |
| $0.022 | 0.000 | 0.0% | $0.022 | $0.022 | $0.021 | 2,923,601 | |
| $0.022 | -0.001 | -4.3% | $0.023 | $0.023 | $0.022 | 2,304,818 | |
| $0.023 | 0.000 | 0.0% | $0.023 | $0.023 | $0.022 | 1,342,739 | |
| $0.023 | -0.002 | -8.0% | $0.025 | $0.025 | $0.023 | 5,787,764 | |
| $0.025 | +0.002 | +8.7% | $0.023 | $0.025 | $0.021 | 7,424,564 | |
| $0.023 | +0.002 | +9.5% | $0.021 | $0.023 | $0.021 | 9,088,944 | |
| $0.021 | +0.002 | +10.5% | $0.019 | $0.021 | $0.019 | 2,843,446 | |
| $0.019 | -0.002 | -9.5% | $0.020 | $0.021 | $0.019 | 3,433,799 | |
| $0.021 | +0.002 | +10.5% | $0.020 | $0.021 | $0.019 | 6,553,748 | |
| $0.019 | 0.000 | 0.0% | $0.020 | $0.020 | $0.019 | 1,611,250 |
Splits
1 split · ASX:AVE · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 98-for-73 | Split |
- Ticker
- Dusseldorf:OEZ
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Nov 15, 2026
Avecho presents at BIO-Europe
Latest deck · Nov 16, 2026
BIO-Europe 2026
Conference · 17 slides
Latest news
Avecho presents at BIO-Europe
Nov 15, 2026
Closed $0.012 (+20.0%) on Nov 16, 2026
September 2026 Quarterly Activities Report & Appendix 4C
Oct 27, 2026
Closed $0.015 (+7.1%) on Oct 28, 2026
Change of Chief Financial Officer
Oct 27, 2026
Closed $0.014 (0.0%) on Oct 27, 2026
Response to ASX Price Query
Oct 21, 2026
Closed $0.017 (+21.4%) on Oct 21, 2026
Avecho to present at the Canaccord Drug and Device Confe
Oct 12, 2026
Closed $0.017 (+6.3%) on Oct 13, 2026
Avecho to present at the ASX SMIDcaps Conference
Sep 22, 2026
Closed $0.02 (-9.1%) on Sep 23, 2026
Avecho enters final stage of Phase III insomnia trial
Aug 30, 2026
Closed $0.023 (0.0%) on Aug 31, 2026
Appendix 4D and Half-year Financial Report
Aug 25, 2026
Closed $0.023 (+9.5%) on Aug 26, 2026
Avecho strengthens BD capability with senior appointment
Aug 23, 2026
Closed $0.019 (-9.5%) on Aug 24, 2026
Small Holding Share Sale Facility Completion
Aug 11, 2026
Closed $0.02 (-4.8%) on Aug 12, 2026
Avecho Biotechnology Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 247 in all · newest Nov 15, 2026 · oldest 2016
- Decks
- 24 decks · latest Nov 16, 2026
Where Avecho Biotechnology Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:AVE · Home listing | ASX | Australia | AUD |
| LS Exchange:A2PLEV | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2PLEV | Lang & Schwarz | Germany | EUR |
| Dusseldorf:OEZ · This page | Dusseldorf | Germany | EUR |
| Frankfurt:OEZ | Frankfurt | Germany | EUR |
| OTC:AVEFF | OTC | United States | USD |
| Stuttgart:OEZ | Stuttgart | Germany | EUR |
Valuation
EV/sales 32.3× against a median of 7.2×: the highest of 3 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $39.98M AUD
- P/E
- Loss
- EV/sales
- 32.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 24.3×
- Gross margin
- 60.7%
- Operating margin
- −485.1%
- Net margin
- −356.8%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Avecho Biotechnology Limited · ASX:AVE | US$30.69M | US$26.46M | n/a | 32.3× | n/a | 24.3× | −356.8% | 0.1× | n/a |
| Enimmune Corporation · TPEX:6564 | US$31.73M | US$26.87M | n/a | 18.4× | n/a | 10.4× | −341.0% | 0.3× | n/a |
| Molecure SA · GPW:MOC | US$31.67M | US$29.61M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Isofol Medical AB · OMXSTO:ISOFOL | US$31.07M | US$19.83M | n/a | n/a | n/a | 3.3× | n/a | 0.0× | n/a |
| Sareum Holdings plc · LSE:SAR | US$31.03M | US$27.78M | n/a | n/a | n/a | 19.9× | n/a | 0.0× | n/a |
| Filana Therapeutics, Inc. · NASDAQ:FLNA | US$30.98M | −US$16.01M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.25 |
| Caribou Biosciences, Inc. · NASDAQ:CRBU | US$30.71M | −US$37.75M | n/a | −4.0× | n/a | 0.4× | n/a | 0.3× | 1.87 |
| Kalaris Therapeutics, Inc. · NASDAQ:KLRS | US$30.47M | −US$51.05M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.47 |
| Pacific Software, Inc. · OTC:PFSF | US$29.86M | US$38.10M | n/a | n/a | n/a | n/a | n/a | n/a | 1.57 |
| NextCure, Inc. · NASDAQ:NXTC | US$29.53M | US$20.81M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.85 |
| NurExone Biologic Inc · TSXV:NRX | US$29.52M | US$28.52M | n/a | n/a | n/a | 23.3× | n/a | 0.0× | 0.00 |
| Median of the others | US$30.85M | US$23.84M | 7.2× | 3.3× | −341.0% | 0.0× | 1.41 |
Team and board
Officers
| Officer | Role |
|---|---|
| Paul Gavin | Chief Executive Officer |
| Subaraj Subramaniam | Chief Financial Officer |
| Roksan Libinaki | Chief Operating Officer |
Board
| Director | Role |
|---|---|
| Greg Collier | Chairman |
| Kathy Connell | Non-Executive Director |
| Ross Murdoch | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Aug 28, 2025 | 0.0% |
| Q4 2024 | Mar 6, 2025 · After close | −14.3% |
| Q4 2022 | Mar 15, 2023 · After close | +12.5% |
| Q2 2022 | Aug 29, 2022 · Before open | −7.7% |
| Q4 2021 | Feb 24, 2022 | −7.1% |
| Q2 2021 | Aug 26, 2021 | 0.0% |
| Q4 2020 | Feb 26, 2021 | −4.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| BIO-Europe 2026 | Conference | 17 slides | Nov 16, 2026 |
| Canaccord Genuity Drug & Device Conference 2026 | Conference | 12 slides | Oct 13, 2026 |
| ASX SMIDcaps Conference 2026 | Conference | 11 slides | Sep 23, 2026 |
| Shareholder Meeting (May 2026) | Shareholder meeting | 22 slides | May 26, 2026 |
| Corporate Update (May 2026) | Corporate update | 13 slides | May 25, 2026 |
| AusBiotech Invest 2025 | Conference | 10 slides | Oct 21, 2025 |
| Shareholder Meeting (May 2025) | Shareholder meeting | 17 slides | May 27, 2025 |
| Investor Presentation (March 2025) | Investor deck | 16 slides | Mar 4, 2025 |
| Shareholder Meeting (May 2024) | Shareholder meeting | 20 slides | May 30, 2024 |
| Investor Presentation (November 2023) | Investor deck | 12 slides | Nov 9, 2023 |
All 24 decks
Financials
Annual, in AUD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.24M | 1.13M | 473.6K | 1.13M | 793.6K | 384.6K | 4.24M | 1.25M | 1.15M | 1.59M |
| Cost of revenue | 486.5K | 460.7K | 517.3K | 336.1K | 285.7K | 143.7K | 1.85M | 553.3K | 93.8K | 329.2K |
| Gross profit | 751.3K | 671.9K | -43.8K | 793.1K | 507.9K | 240.9K | 4.02M | 699.0K | 1.06M | 1.26M |
| Research and development | 4.31M | 3.59M | 2.12M | 1.59M | 2.13M | 187.6K | 166.0K | 1.03M | 2.27M | 2.83M |
| Selling, general and administrative | 2.07M | 1.99M | 2.43M | 1.49M | 2.83M | 2.74M | 1.29M | 1.32M | 4.41M | 3.88M |
| Operating income | -6.00M | -4.96M | -4.59M | -3.06M | -4.55M | -3.39M | 1.57M | -5.33M | -9.06M | -9.29M |
| Depreciation and amortization | 137.1K | 144.9K | 178.7K | 230.4K | 428.6K | 536.6K | 683.5K | 725.6K | 776.5K | 2.47M |
| EBITDA | -5.87M | -4.81M | -4.41M | -2.83M | -4.12M | -2.85M | 2.26M | -4.60M | -8.28M | -6.82M |
| Interest expense | 461.4K | 57.1K | 15.4K | 6.35K | 9.97K | 5.92K | 11.0K | 90.5K | 36.0K | 110.0K |
| Income before tax | -6.41M | -3.12M | -4.51M | -2.96M | -4.54M | -3.00M | 503.9K | -4.68M | -9.63M | -19.1M |
| Income tax | -2.00M | -1.64M | -1.08M | -623.0K | -1.13M | -360.0K | -346.0K | -685.0K | -1.01M | -1.83M |
| Net income | -4.42M | -3.12M | -3.44M | -2.34M | -3.42M | -2.63M | 850.0K | -3.99M | -8.62M | -17.3M |
| Earnings per share, basic | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | -0.00 | -0.01 | -0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.66M | 2.37M | 5.50M | 1.47M | 3.26M | 1.87M | 3.21M | 2.11M | 2.90M | 6.09M |
| Short-term investments | 85.7K | 56.7K | 454.7K | 205.0K | ||||||
| Receivables | 2.20M | 2.25M | 1.10M | 746.0K | 1.13M | 479.1K | 755.4K | 292.3K | 212.3K | 274.3K |
| Inventory | 8.07K | 137.5K | 97.1K | 402.0K | 196.7K | 100.0K | 148.8K | 99.8K | 291.6K | 237.0K |
| Current assets | 7.06M | 4.81M | 7.00M | 2.85M | 4.81M | 2.69M | 4.28M | 3.25M | 5.80M | 10.2M |
| Property, plant and equipment | 33.7K | 170.8K | 315.7K | 468.1K | 336.2K | 233.0K | 179.9K | 159.6K | 251.0K | 384.9K |
| Total assets | 7.11M | 5.00M | 7.32M | 3.35M | 5.25M | 3.35M | 5.32M | 4.80M | 8.24M | 13.4M |
| Accounts payable | 103.7K | 60.6K | 94.9K | 191.2K | 75.2K | 110.3K | 96.6K | 132.4K | 1.08M | 571.0K |
| Current liabilities | 709.2K | 1.71M | 843.3K | 745.5K | 695.7K | 603.6K | 544.8K | 872.5K | 1.71M | 1.66M |
| Total debt | 14.5K | 1.08M | 175.2K | 246.1K | 93.9K | 166.2K | 97.2K | |||
| Total liabilities | 5.55M | 1.73M | 941.5K | 920.7K | 709.4K | 700.2K | 556.1K | 902.0K | 1.84M | 1.71M |
| Shareholders' equity | 1.56M | 3.27M | 6.38M | 2.42M | 4.54M | 2.65M | 4.76M | 3.90M | 6.40M | 11.6M |
| Shares outstanding | 3.27B | 3.12B | 2.27B | 1.84B | 1.80B | 1.59B | 1.58B | 1.57B | 1.30B | 1.29B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.10M | -3.97M | -3.18M | -1.67M | -3.10M | -1.42M | 1.19M | -2.19M | -6.42M | -6.41M |
| Capital spending | 0 | 0 | -5 | -53.1K | -202.8K | -5.15K | -5.15K | -424 | -55.6K | -62.3K |
| Free cash flow | 1.10M | -3.97M | -3.18M | -1.72M | -3.30M | -1.43M | 1.19M | -2.19M | -6.48M | -6.47M |
| Cash from investing | 0 | -15.7K | 0 | -53.1K | -202.8K | -5.15K | 11.1K | 41.8K | 53.5K | 108.8K |
| Cash from financing | 1.19M | 854.6K | 7.22M | -78.2K | 4.69M | -82.5K | -89.4K | 1.36M | 3.17M | 3.17M |
| Dividends paid | -4.40M | |||||||||
| Share buybacks | -187.2K | 0 | -716.5K | 1.99K | -294.2K | 0 | -13.5K | -186.2K | ||
| Change in cash | 2.29M | -3.13M | 4.04M | -1.80M | 1.39M | -1.34M | 1.10M | -787.4K | -3.19M | -6.30M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Avecho presents at BIO-Europe | Nov 15, 2026 | Operations update | ASX |
| September 2026 Quarterly Activities Report & Appendix 4C | Oct 27, 2026 | Quarterly report | ASX |
| September 2026 Quarterly Activities Report & Appendix 4C | Oct 27, 2026 | Quarterly report | ASX |
| Change of Chief Financial Officer | Oct 27, 2026 | Other filings | ASX |
| Response to ASX Price Query | Oct 21, 2026 | Explanation request | ASX |
| Response to ASX Price Query | Oct 21, 2026 | Explanation request | ASX |
| Avecho to present at the Canaccord Drug and Device Confe | Oct 12, 2026 | Other filings | ASX |
| Avecho to present at the ASX SMIDcaps Conference | Sep 22, 2026 | Other filings | ASX |
| Avecho enters final stage of Phase III insomnia trial | Aug 30, 2026 | Operations update | ASX |
| Appendix 4D and Half-year Financial Report | Aug 25, 2026 | Interim report | ASX |
Show 200 filings
This page holds 200 of 243 filings. Open Filings
Cap table
Built by 6ix from Avecho Biotechnology Limited’s releases
- Common shares
- 3,863,725,873
- Fully diluted
- 3,863,725,873
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 3,863,725,873 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 3,863,725,873 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Greg Collier | Chairman · Since at least Nov 4, 2026 |
| Kathy Connell | Non-Executive Director · Since at least Nov 4, 2026 |
| Paul Gavin | Chief Executive Officer · Since at least Jun 29, 2026 |
| Roksan Libinaki | Chief Operating Officer · Since at least Nov 5, 2026 |
| Ross Murdoch | Non-Executive Director · Since Feb 11, 2016 |
| Subaraj Subramaniam | Chief Financial Officer · Since at least Oct 27, 2026 |
Log in to ask 6ix AI your own questions about Avecho Biotechnology Limited.